Molecular Cytogenetic Aberrations in Thai Patients with Multiple Myeloma

Authors

  • Pitichai Phornsarayuth Mahidol University
  • Veerawat KorKiasakul Mahidol University
  • Teeraya Puavilai Mahidol University
  • Kochawan Boonyawat Mahidol University
  • Pimjai Niparuck Mahidol University
  • Suporn Chuncharunee Mahidol University
  • Takol Chareonsirisuthigul Mahidol University
  • Budsaba - Rerkamnuaychoke Mahidol University

Keywords:

multiple myeloma, Fluorescence, FISH, molecular cytogenetic, bone marrow

Abstract

Cytogenetic abnormality plays an important role in prognosis of patients with multiple myeloma (MM). Conventional cytogenetic assay reveals limited results. In this study, we performed interphase fluorescence in situ hybridization (I-FISH) analysis to explore the incidence of cytogenetic abnormalities in patients with MM. Heparinized bone marrow was evaluated by FISH assay. Four FISH probes specific for deletion 13, deletion 17, t(4;14), and t(11;14) were used. Sixty-six patients were included from March 2013 to February 2014. The incidence of the abnormality was found in 35 of 66 cases (53.03%). Deletions of 13q14 region (D13S319) were detected in 19 cases (54.29%). Translocations involving 14q32 region were observed in 10 cases (28.57%) including t(4;14) and t(11;14) for 6 and 4 cases, respectively. Deletions of 17p13 region (TP53) were detected in 5 cases (14.29%). Furthermore, we found other abnormalities, such as, 3-4 copies of 11q13 (28.57%), 14q32 deletion (8.57%) and trisomy 17 (2.86%). It was unable to evaluate the results in 8/66 patients (12.1%). Clinical outcome and prognostic values are being followed. The most common cytogenetic abnormality finding in this study is 13q14.3 deletion. The prognostic impact on response to chemotherapy and survival among these patients needs to be determined in long-term follow-up.

Author Biographies

Pitichai Phornsarayuth, Mahidol University

Department of Pathology, Faculty of Medicine Ramathibodi Hospital

Veerawat KorKiasakul, Mahidol University

Department of Pathology, Faculty of Medicine Ramathibodi Hospital

Teeraya Puavilai, Mahidol University

Department of Medicine, Faculty of Medicine Ramathibodi Hospital

Kochawan Boonyawat, Mahidol University

Department of Medicine, Faculty of Medicine Ramathibodi Hospital

Pimjai Niparuck, Mahidol University

Department of Medicine, Faculty of Medicine Ramathibodi Hospital

Suporn Chuncharunee, Mahidol University

Department of Medicine, Faculty of Medicine Ramathibodi Hospital

Takol Chareonsirisuthigul, Mahidol University

Department of Pathology, Faculty of Medicine Ramathibodi Hospital

Budsaba - Rerkamnuaychoke, Mahidol University

Department of Pathology, Faculty of Medicine Ramathibodi Hospital

References

Bergsagel PL, Chesi M (2013) Molecular classification and risk stratification of myeloma. Hematol Oncol 31: 38-41.

Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, Jager U, Fiegl M, Geissler K and Ludwig H (1995) Interphase Fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammophathy of undermined significance. Blood 86(10): 3915-3921.

Firkin F (2009) Screening for multiple myeloma. Aust Prescr 32: 92-94.

Fonseca R and Bergsagel P (2009) Diagnosis and Genetic Classification of Multiple Myeloma. In: Rajkumar SV (eds) Treatment of Multiple Myeloma and Related Disorders. Cambridge University Press, New York, pp 1-10.

Gmidene A, Avet-Loiseau H, Sennana H, Abdallah IB, Khlif A, Meddeb B, Elloumi M and Saad A (2011) Molecular cytogenetic aberrations in Tunisian patients with multiple myeloma identified by cIg-FISH in fixed bone marrow cells. Cytogenet Genome Res 136(1):44-49.

Liebisch P and Dohner H (2006) Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer 42: 1520-1529.

Lom KV, Hagemeijer A, Smit EME and Lowenberg B (1993) In situ hybridization on May-Grunwald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allows detection of cell-lineage-specific cytogenetic abnormalities. Blood 82(3): 884-888.

Potacova V, Stossova J, Buresova I, Kovarova L, Almasi M, Penka M and Hajek R (2011) Sample processing and methodological pitfalls in multiple myeloma research. Klin Onkol 24: 18-23.

Put N, Lemmens H, Wlodarska I, Konings P, Moreau Y, Hagemeijer A, Vanderberghe P and Michaux L (2010) Interphase fluorescence in situ hybridization on selected plasma cells in superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. Genes Chromosomes cancer 49: 991-997.

Rajkumar SV (2013) Initial treatment of multiple myeloma. Hematol Oncol 31: 33-37.

Sawyer, JR (2011) The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 204: 3-12.

Shin SY, Jang S, Park CJ, Lee JH, Lee KH, Suh C, Lim SE and Seo EJ (2012) Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma. Int J Lab Hematol 34(5): 541-546.

Wiktor A and Dyke DLV (2004) Combined cytogenetics testing and fluorescence in situ hybridization analysis in the study of chronic lymphocytic leukemia and multiple myeloma. Cancer Genet Cytogenet 153: 73-76.

Vanwier S and Fonseca R (2005) Detection of chromosome 13 deletions by Fluorescenct in situ hybridization. In: R.D. Brown and P.J. Ho (eds.) Multiple myeloma: method and protocols. Humana Press Inc., Totowa New Jersey. pp. 59-69.

Xiao G, Chunming L, Run Z, Ruifang Y, Xiaoyan Q, Hairong Q, Jiaren X, Hua L, Jianyong L and Lijuan C (2012) Fluorescence in situ hybridization analysis of chromosome aberration in 60 Chinese patients with multiple myeloma. Med Oncol 29(3): 2200-2206.

Downloads

Published

2016-06-19

Issue

Section

Research Articles